Insulin resistance in euglycemic cirrhosis

Amitava Goswami, Narendra Bhargava, Sunil Dadhich, Ganaraj Kulamarva
Dr Sampurnanand Medical College, Jodhpur, India

Abstract

Background Insulin resistance (IR) is associated with hepatic fibrosis and cirrhosis, regardless of its etiology but the mechanism of hyperinsulinemia in cirrhosis is still unclear. The current study was designed to assess hyperinsulinemia and pancreatic β-cell function in euglycemic cirrhosis of varied etiology.

Methods A cross sectional case control study of 100 subjects. IR was assessed by the Homeostasis Model Assessment (HOMA) and quantitative insulin sensitivity check index in euglycemic cirrhosis of varied etiology and in different stages of cirrhosis. HOMA-β was calculated for insulin secretion ability of pancreatic β-cells in different stages of cirrhosis.

Results Overall IR in euglycemic cirrhosis was seen in 68.5%. IR was seen in the order hepatitis C (100%), non-alcoholic fatty liver disease (100%), autoimmune hepatitis (100%), hepatocellular carcinoma (80%), alcoholic liver disease (72%) and hepatitis B (45%). HOMA-IR value was raised in Child Turcotte Pugh (CTP) score >9 (P value 0.0004) and model of end stage liver disease (MELD) score >15 (P value 0.02). HOMA-β was raised in CTP score >9 (P value 0.02) and MELD score >15 (P value 0.0003). HOMA-β level among diabetic controls was 27.1±7.7 compared to 154.6±80.7 in euglycemic cases (P value <0.0001).

Conclusion IR is common in euglycemic cirrhosis and with advancement of liver disease; there is a compensatory increase in pancreatic β-cell insulin secretion to overcome the IR. However, over a period of time with fall in β-cell function development of hepatogenous diabetes may occur.

Keywords Homeostatic model assessment, quantitative insulin sensitivity check index, Child Turcotte Pugh, model of end stage liver disease, hepatocellular carcinoma

Ann Gastroenterol 2014; 27 (3): 237-243

Introduction

An association between diabetes mellitus and liver cirrhosis was first described by Bohan [1] and named as hepatogenous diabetes by Megyesi et al, in which 57% of cirrhotic patients showed increased insulin resistance (IR) [2]. Currently, it is still unclear whether type 2 diabetes mellitus, in the absence of other risk factors contributing to metabolic syndrome (obesity and hypertriglyceridemia), could be a risk factor for the development and progression of liver disease [3-5]. On the other hand, the diabetes which develops as a complication of cirrhosis is known as “hepatogenous diabetes” and is not recognized by the American Diabetes Association and the World Health Organization as a specific independent entity [6]. IR is defined where a normal or elevated insulin level produces an attenuated biological response [7]; classically this refers to impaired sensitivity to insulin-mediated glucose disposal [8]. Compensatory hyperinsulinemia occurs when pancreatic β-cell secretion increases to maintain normal blood glucose levels in the setting of peripheral IR in muscle and adipose tissue. IR results from defects either at the receptor level or in insulin receptor substrates molecules [9]. However, whether the hyperinsulinaemia in cirrhosis is a consequence of increased pancreatic insulin secretion, decreased hepatic insulin removal, or impaired feedback regulation of insulin secretion is still doubtful. So the current study was designed with a hypothesis that IR progressively increases with advancement of liver disease and identification of IR may access the risk for development of hepatogenous diabetes and hepatocellular carcinoma (HCC).

The aim of the study was to investigate: 1) IR in euglycemic cirrhosis of varied etiology, 2) IR in different stages of cirrhosis. 3) Pancreatic β-cell Insulin secretions in relation to stages of cirrhosis.
Patients and methods

A cross sectional case control study of one hundred patients. The study was conducted in the Department of Gastroenterology (Dr Sampurnanand Medical College) over a period of 6 months (April-September 2013). The study was approved by the ethics committee of the medical college. After written consent, subjects were counselled and explained about the objectives of the study by a qualified medical doctor. Detailed personal history was taken using a standard questionnaire and 5 mL of fasting blood sample was collected.

Inclusion criteria comprised: 1) euglycemic cirrhotic patients (fasting blood sugar <126 mg/dL), diagnosis of cirrhosis was based on histopathological evidence (liver biopsy) or unequivocal clinical grounds (chronic liver disease stigmata, jaundice, ascites, esophageal varices), impaired liver function tests and ultrasonographic features consistent with cirrhosis (diffuse alteration and nodular transformation of liver parenchyma, and signs of portal hypertension); 2) patients with HCC, diagnosed by cytological or histological examination of hepatic focal lesions or according to the following established criteria: ultrasound examination, a-fetoprotein >400 ng/mL, computed tomography scan and/or magnetic resonance imaging of the upper abdomen; 3) body mass index (BMI) ≤25 kg/m²; 4) diseased controls were cirrhotic patients with recently diagnosed diabetes mellitus. The patients selected for diseased controls were cirrhotic patients of varied etiology, who had a recent onset of diabetes mellitus within a period of 2 years.

Exclusion Criteria: 1) Known type 2 diabetes mellitus or fasting blood sugar >126 mg/dL (except controls); 2) BMI >25 kg/m² (except controls); 3) renal failure; 4) pregnancy; 5) thyroid dysfunction.

Laboratory assessment

Venous blood samples were taken in the morning after 8-h overnight fasting. Hepatitis B surface antigen (HBsAg), anti-HBV surface antigen (anti-HBs), anti-HBV core antigen (anti-HBc), and hepatitis B “e” antigen (HBeAg) were determined by using commercial assays (Abbott Diagnostic Division, Wiesbaden; Germany). Antibodies against hepatitis C (anti-HCV) were determined using a sensitive commercial ELISA (Xcyton, Bangalore, India). Serum HCV-RNA were tested using the Roche Amplicor version 2.0 (Roche Molecular System, Pleasenton, CA). Insulin was measured by chemiluminescence immunoassay on an Advia Centaur analyzer (Bayer AG, Germany). Because pancreatic insulin secretion is pulsatile, for each subject we used the mean of three samples taken at 5-min intervals. diabetes mellitus was diagnosed using the American Diabetes Association criteria [10]: fasting plasma glucose >126 mg/dL (confirmed on a subsequent day in the absence of unequivocal hyperglycemia) or symptoms of hyperglycemia and casual plasma glucose >200 mg/dL.

IR measurement

IR was assessed by the Homeostasis Model Assessment method for the evaluation of IR (HOMA-IR). HOMA was first developed in 1985 by Matthews et al [11]. It is a method used to quantify IR and β-cell function from basal (fasting) glucose and insulin concentrations. HOMA is a model of the relationship of glucose and insulin dynamics that predicts fasting steady-state glucose and insulin concentrations for a wide range of possible combinations of IR and β-cell function. HOMA-IR = (glucose × insulin)/22.5; insulin concentration is reported in μU/mL and glucose in mmol/L. The constant of 22.5 is a normalizing factor; i.e., the product of normal fasting plasma insulin of 5 μU/mL, and the normal fasting plasma glucose of 4.5 mmol/L typical of a “normal” healthy individual=22.5. Value of HOMA-IR more than 1.64 implied the presence of abnormally high IR [12]. Quantitative insulin sensitivity check index (QUICKI), as an alternative surrogate marker of IR, computed as 1/[log insulin (μU/mL) + log fasting blood sugar (FBS) (mg/dL)]. Value <0.35 is suggestive for IR. QUICKI is an empirically-derived mathematical transformation of FBS and plasma insulin concentrations that provides a consistent and precise index of insulin sensitivity with better positive predictive power [13]. HOMA-β a parameter reflecting the insulin secretion ability of pancreatic β-cells, was calculated as [360 × insulin (μU/mL)]/FBS (mg/dL) -63. Estimation with the help of HOMA-β model parallels equally with that of the euglycemic clamp method (r = 0.88) [14].

Statistical analysis

HOMA calculator 2.2 was used to calculate the HOMA IR and HOMA-β values while QUICKI values were calculated with a scientific calculator. Parametric data are expressed as mean values ± standard deviation (SD) and categorical variables as percentages. Chi-square test or Fisher’s exact test were used for the comparison of dichotomous variables and Student’s t test for continuous variables. Whenever more than 2 continuous variables were present, ANOVA one-way analysis was used for calculating the P values. A P value <0.05 was considered statistically significant. Spearman and Pearson’s coefficient correlation were used to compare the regression coefficient between the two groups. All data were analyzed using the SAS 8.0 statistical package.

Results

From April 2013 to September 2013, 70 patients of euglycemic cirrhosis were included in the study group and another 30 diseased controls (recent onset diabetes mellitus) were also enrolled.

Patient characteristics

Euglycemic cirrhosis cases: The mean age of cases of euglycemic cirrhosis was 52.3±13.7 yrs with M: F 6:1. Mean
BMI was 22.6±2.4 kg/m². Alcoholic liver disease (ALD) (51%) was the most common etiology followed by hepatitis B (HBV) (31%), HCV (6%), non-alcoholic fatty liver disease (NAFLD) (6%) and autoimmune hepatitis (AIH) (6%) respectively (Table 1). Ten cases of euglycemic HCC were present among which 8 cases were due to HBV-related cirrhosis and only 2 cases due to HCV-related cirrhosis. Most of the patients had advanced liver disease; that is Child Turcotte Pugh’s score (CTP) ≥10 (60%), CTP score 7-9 (31%), and CTP score 5-6 (9%). Likewise, 63% of cases had model of end-stage liver disease (MELD) score >15; 26% had MELD score 10-15; and 11% had MELD score <10. The mean FBS level was 84.7±20.2 mg/dL, and the mean fasting insulin was 11.8±6.7 μU/mL. The overall IR in the euglycemic cirrhotic patients was 68.5%. The mean levels of HOMA-IR, QUICKI and HOMA - β were 2.54±1.71, 0.34±0.01 and 154.6±80.7 respectively.

**Diabetic (diseased) controls:** The mean age group and M: F ratio was comparable with the cases, 52.2±8.1 yrs and 13:2 respectively (P>0.05). The etiology of cirrhosis was different from the cases; NAFLD (53%) was the most common etiology followed by ALD (27%), HBV (13%) and HCV (7%) respectively. There were 4 diseased controls with HCC and diabetes mellitus; all were caused by HBV-related cirrhosis. The mean FBS and fasting insulin were 198±47.3 mg/dL and 9.9±2.5 μU/mL respectively. IR was universal among the diseased diabetic controls with mean HOMA-IR and QUICKI levels of 4.9±1.9 and 0.31±0.01 respectively (P<0.0001). IR was much higher among the diabetic controls than the euglycemic cirrhotic cases. There was a significant difference in the HOMA-β levels between the diabetic controls and euglycemic cirrhotic cases (P<0.0001). The mean HOMA-β level in the diseased controls was 27.1±7.7 as compared to 154.6±80.7 in the cases.

**IR of varied etiology in euglycemic cirrhosis**

The Spearman coefficient correlation between IR and varied euglycemic cirrhosis was very significant (R=1). Pearson regression coefficient was 0.96. IR was seen in all cases of NAFLD, AIH and HCV (genotype 3) related euglycemic cirrhosis (Table 2). Eighty percent of cases of euglycemic HCC and 72% with alcoholic cirrhosis had IR, while least among cases of HBV-related cirrhosis (45%). HOMA-IR was highest among HBV (5.7±0.7) and least among HBV-related euglycemic cirrhosis (1.9±1.5) (Fig. 1). Cases of HCV cirrhosis, alcoholic cirrhosis and NAFLD-related cirrhosis had advanced liver disease with high CTP and MELD score while most of the cases with HCC had lower mean CTP and MELD score (8.8, 11.4 respectively), suggesting that IR occurs early in HCC.

**IR in different stages of cirrhosis**

**CTP score:** An increasing trend in IR was seen from CTP-A to CTP-B (33%, 54%; P=0.08), though statistically nonsignificant. The advanced cirrhotics with CTP ≥10 had

---

### Table 1 Baseline characteristics

| Variables                                | Cases n=70 (%) | Diseased controls n=30 (%) | P value |
|------------------------------------------|----------------|----------------------------|---------|
| **Etiology**                             |                |                            |         |
| Alcohol                                  | 36 (51)        | 8 (27)                     | 0.01    |
| HBV                                      | 22 (31)        | 4 (13)                     | 0.03b   |
| HCV                                      | 4 (6)          | 2 (7)                      | 0.13    |
| NAFLD                                    | 4 (6)          | 16 (53)                    | 0.001b  |
| AIH                                      | 4 (6)          | 0 (0)                      | 0.20    |
| HCC                                      | 10 (14)        | 4 (13)                     | 0.16    |
| **Age (years)**                          |                |                            | 0.49    |
| Mean±SD                                  | 52.3±13.7      | 52.2±8.1                   |         |
| Range                                    | (23-75)        | (41-67)                    |         |
| M:F                                      | 6:1            | 13:2                       | 0.27    |
| BMI (kg/m²)                              |                |                            | 0.005a  |
| Mean±SD                                  | 22.6±2.4       | 24.1±2.3                   |         |
| Range                                    | (19.2-31.6)    | (19-28.6)                  |         |
| CTP Score                                | 9.9±2.1        | 7.4±1.8                    | <0.001b |
| A                                        | 6 (9)          | 12 (40)                    |         |
| B                                        | 22 (31)        | 14 (47)                    |         |
| C                                        | 42 (60)        | 4 (13)                     |         |
| MELD Score                               | 198±3          | 11.5±5.5                   | <0.0001b|
| <10                                      | 8 (11)         | 14 (47)                    |         |
| 10-15                                    | 18 (26)        | 10 (33)                    |         |
| >15                                      | 44 (63)        | 6 (20)                     |         |
| FBS (mg/dL)                              | 84.7±20.2      | 198±47.3                   | <0.0001b|
| Range                                    | (53-125)       | (145-342)                  |         |
| Fasting Serum Insulin (µU/mL)            |                |                            | 0.03b   |
| Mean±SD                                  | 11.8±6.7       | 9.9±2.5                    |         |
| Range                                    | (2.7-33.3)     | (6.1-16)                   |         |
| HOMA-IR                                  |                |                            | <0.0001b|
| Mean±SD                                  | 2.54±1.71      | 4.9±1.9                    |         |
| Range                                    | (0.5-7.02)     | (2.72-8.59)                |         |
| QUICKI                                   |                |                            | <0.0001b|
| Mean±SD                                  | 0.34±0.04      | 0.31±0.01                  |         |
| Range                                    | (0.29-0.44)    | (0.28-0.33)                |         |
| HOMA-β                                   |                |                            | <0.0001b|
| Mean±SD                                  | 154.6±80.7     | 27.1±7.7                   |         |
| Range                                    | (37.4-384)     | (7.4-37.4)                 |         |

*P value <0.05, bP value <0.01; P value were determined using the chi-square test or Fisher's exact test for the dichotomous variables and Student's t test for continuous variables. CTP: child turcotte pugh; MELD: model of end-stage liver disease; HBV, hepatitis B virus; HCV, hepatitis C virus; NAFLD, non-alcoholic fatty liver disease; AIH, autoimmune hepatitis; HCC, hepatocellular carcinoma; FBS, fasting blood sugar; HOMA, homeostatic model assessment; QUICKI, quantitative insulin sensitivity check index.*

---

*Annals of Gastroenterology 27*
Table 2 Insulin resistance of varied etiology in euglycemic cirrhosis

| Etiology  | N (%) | CTP   | MELD  | IR (%) | Pearson/spearman coefficient (r/R) | HOMA-IR   | QUICKI   | HOMA-β   |
|-----------|-------|-------|-------|--------|-----------------------------------|-----------|----------|----------|
| ALD Mean±SD | 36 (51) | 10.1±2.3 | 21.1±8.9 | 26 (72) | 2.4±1.3                          | 0.34±0.03 | 160.1±96.4 |
| HBV Mean±SD | 22 (31) | 9.2±1.8 | 16±7.9 | 10 (45) | r=0.96 R=1                          | 1.9±1.5 | 0.37±0.05 | 143.4±65.5 |
| HCV Mean±SD | 4 (6) | 12±2.3 | 18±2.9 | 4 (100) |                                  | 5.7±0.7 | 0.29±0.01 | 114.4±27.8 |
| NAFLD Mean±SD | 4 (6) | 10±0.6 | 20±4.6 | 4 (100) |                                  | 4.9±2.4 | 0.30±0.02 | 185.9±71.3 |
| AIH Mean±SD | 4 (6) | 9±2.5 | 16±7 | 4 (100) |                                  | 2±0.2 | 0.34±0.01 | 175.5±1.7 |
| HCC Mean±SD | 10 (14) | 8.8±2 | 11.4±3 | 8 (80) |                                  | 3.5±1.6 | 0.32±0.04 | 117.9±55.6 |

R, spearman coefficient correlation; r, pearson coefficient correlation; CTP, child turcotte pugh; MELD, model of end-stage liver disease; HOMA, homeostatic model assessment; IR, insulin resistance; QUICKI, quantitative insulin sensitivity check index; ALD, alcoholic liver disease; HBV, hepatitis B virus; HCV, hepatitis C virus; NAFLD, non-alcoholic liver disease; AIH, autoimmune hepatitis; HCC, hepatocellular carcinoma

Figure 1 Insulin resistance in varied etiology of euglycemic cirrhosis
HCC, hepatocellular carcinoma; AIH, autoimmune hepatitis; NAFLD, non-alcoholic fatty liver disease; HCV, hepatitis C virus; HBV, hepatitis B virus; ALD, alcoholic liver disease

a statistically significant IR as compared to other groups (P=0.05). HOMA-IR is significantly higher (3.08±1.92) in cases with CTP ≥10 as compared to CTP-A and B (Table 3). QUICKI as a surrogate marker of IR showed similar correlation with HOMA-IR, it was significantly lower in advanced cirrhosis with CTP-C (P=0.02). Diseased controls with recent onset of diabetes mellitus had higher IR value than its euglycemic counterpart (Fig. 2). A significant fall in QUICKI in diseased controls with CTP score >9 was seen as compared to CTP score <9 (P=0.004), but no significant rise in HOMA-IR was seen among the diseased controls with CTP-C status (P=0.22).

MELD score was divided into three groups, i.e., <10; 10-15; and >15, which correlated well with CTP score. Similar to CTP score, the IR is most commonly seen in cases with advanced cirrhosis with MELD score >15 (82%, P=0.03). HOMA-IR and QUICKI correlated well, and a higher IR was seen in MELD score >15 as compared to MELD score 10-15 and less than 10 (P value 0.02 and 0.01, respectively). Controls (diseased) had a higher HOMA-IR value, but no significant alteration was seen among the three different groups of MELD score (Table 4).

Pancreatic β-cell insulin secretions correlation with stages of cirrhosis (HOMA-β)

HOMA-β a parameter reflecting the insulin secretion ability of pancreatic β-cells was evaluated in euglycemic cirrhotic with different CTP score and MELD score. HOMA-β is seen significantly elevated in patients with CTP-C and MELD score >15 (P values 0.02 and 0.003, respectively). HOMA-β
Table 3 HOMA-IR and HOMA-β correlation with CTP score

| CTP score | Cases (n=70) | Diseased controls (n=30) |
|-----------|--------------|--------------------------|
|           | A (6)        | B (22)                   | C (42) | P value | A (12) | B (14) | C (4) | P value |
| HOMA-IR   |              |                          |        |         |        |        |       |         |
| Mean±SD   | 2.05±1.39    | 1.66±0.75                | 3.08±1.92 | 0.004   | 4.84±2.04 | 4.55±1.83 | 6.45±1.44 | 0.22   |
| QUICKI    |              |                          |        |         |        |        |       |         |
| Mean±SD   | 0.35±0.04    | 0.36±0.04                | 0.33±0.04 | 0.02    | 0.31±0.01 | 0.31±0.01 | 0.29±0.01 | 0.004  |
| HOMA-β    |              |                          |        |         |        |        |       |         |
| Mean±SD   | 121.6±64.8   | 123.1±60.6               | 175.8±86.1 | 0.02    | 27.7±10.8 | 25.9±3.3 | 29.5±9.1 | 0.69   |

*p values were calculated using the ANOVA one way test for continuous variables.

HOMA-IR, homeostatic model assessment of insulin resistance; QUICKI, quantitative insulin sensitivity check index; HOMA-β, homeostatic model assessment of β-cell sensitivity; CTP, Child Turcotte Pugh

Table 4 HOMA-IR and HOMA-β correlation with MELD score

| MELD score | Cases (n=70) | Diseased controls (n=30) |
|------------|--------------|--------------------------|
|            | <10 (8)      | 10-15 (18)               | >15 (44) | P value | <10 (14) | 10-15 (10) | >15 (6) | P value |
| HOMA-IR    |              |                          |        |         |        |        |       |         |
| Mean±SD    | 1.99±1.24    | 1.92±1.39                | 2.94±1.83 | 0.02    | 5.26±2.39 | 4.5±1.76 | 4.79±0.50 | 0.64   |
| QUICKI     |              |                          |        |         |        |        |       |         |
| Mean±SD    | 0.35±0.03    | 0.36±0.05                | 0.33±0.03 | 0.01    | 0.30±0.01 | 0.31±0.01 | 0.30±0.01 | 0.05   |
| HOMA-β     |              |                          |        |         |        |        |       |         |
| Mean±SD    | 134.7±61.5   | 97.2±45.6                | 181.7±82.5 | 0.0003  | 26.32±9.97 | 29.74±5.75 | 24.7±2.5 | 0.4    |

*p values were calculated using the ANOVA one way test for continuous variables.

HOMA-IR, homeostatic model assessment of insulin resistance; QUICKI, quantitative insulin sensitivity check index; HOMA-β, homeostatic model assessment of β-cell sensitivity; CTP, child Turcotte Pugh; MELD, model of end-stage liver disease

Figure 2 HOMA-IR in euglycemic and diabetic cirrhosis

CTP, Child Turcotte Pugh; MELD, model for end-stage liver disease; DM, diabetes mellitus

level is lower in MELD score 10-15 than in MELD score <10, but patients with MELD score >15 have a much higher value as compared to other groups; likewise, HOMA-β levels were comparable between patients with CTP A and B but significantly elevated in CTP C (Fig. 3). HOMA-β values were the lowest in the diabetic controls (27.1±7.7), with no significant change in the three different groups of CTP or MELD scores.

Discussion

In our study, IR in euglycemic cirrhosis was seen in 68.5%, whereas it was universally present in cirrhotic patients with recent onset diabetes. The cut off of IR was taken with HOMA-IR value >1.64 and QUICKI <0.35 which has been validated in many studies [12,15]. Our study shows that

Insulin resistance in euglycemic cirrhosis 241

Annals of Gastroenterology 27
HOMA-IR in euglycemic cirrhosis is minimally elevated in CTP <10 and MELD <15, but it significantly rises with CTP score ≥10 or MELD score >15.

HCV per se is an important factor for the development of IR. IR parallels the liver fibrosis stage [16,17] and is associated with a reduced level of sustained virological response to treatment. HCV genotypes 1, 3 and 4 are associated with more severe IR [17]. In the present study all the patients with HCV were of genotype 3, and IR was seen universally.

Chronic ALD is mediated by combined effects of IR and toxic injury. Hepatic IR is caused by defects in intracellular signaling, including impairments in receptor binding and receptor tyrosine kinase activation. Ethanol also inhibits tyrosine phosphorylation of insulin receptor substrate proteins, needed to transmit insulin and insulin-like growth factor receptor signals [18-20]. In the present study IR in ALD were seen 72% cases, but IR occurred mainly with advancement in liver disease that is CTP-C status or MELD score >15. IR is a very common phenomenon in NAFLD [21]. In our study, almost all patients with NAFLD had IR in our study, which is in agreement to the concept that IR is the primary event in NAFLD. We also stated that IR was least commonly associated with HBV-related liver disease and HOMA-IR rises only after advancement in the stage of liver disease. The main limitation of our study was that we did not measure the vitamin D levels of the patients. There is increasing belief that with fall in vitamin D levels there may be an increase in IR among cirrhotic patients.

Several studies suggest that type 2 diabetes mellitus may have an etiological role in chronic liver disease and HCC regardless of alcohol and viruses [5]. In a recent case-control study that included 465 patients, diabetes mellitus prevalence was higher in patients with HCC than in controls (31.2% vs 12.7%, OR 3.12, 95% CI: 2.22-4.43). The diabetes mellitus had been diagnosed prior to the occurrence of HCC in 84% of cases with an average duration of 181.4 months indicating that it was type 2 diabetes mellitus in most cases [23]. The above data suggests that type 2 diabetes mellitus itself might be a risk factor for the occurrence of HCC. In the present study IR was found in 80% of cases of HCC, and most of the cases had low MELD and CTP score. It is therefore suggested that IR, primarily seen in type 2 diabetes mellitus, might have a role in hepatic carcinogenesis. IR with compensatory hyperinsulinemia has been implicated in the etiology of certain cancers, including colon, endometrial, possibly pancreatic, renal-cell cancers and breast cancer [8,24].

A decrease in islet mass and/or β-cell dysfunction is a pathogenetic mechanism for type 2 diabetes mellitus [25]. In the present study we found a significant fall in β-cell function for the occurrence of HCC. In the present study IR was found in 80% of cases of HCC, and most of the cases had low MELD and CTP score. It is therefore suggested that IR, primarily seen in type 2 diabetes mellitus, might have a role in hepatic carcinogenesis. IR with compensatory hyperinsulinemia has been implicated in the etiology of certain cancers, including colon, endometrial, possibly pancreatic, renal-cell cancers and breast cancer [8,24].

A decrease in islet mass and/or β-cell dysfunction is a pathogenetic mechanism for type 2 diabetes mellitus [25]. In the present study we found a significant fall in β-cell function for the occurrence of HCC. In the present study IR was found in 80% of cases of HCC, and most of the cases had low MELD and CTP score. It is therefore suggested that IR, primarily seen in type 2 diabetes mellitus, might have a role in hepatic carcinogenesis. IR with compensatory hyperinsulinemia has been implicated in the etiology of certain cancers, including colon, endometrial, possibly pancreatic, renal-cell cancers and breast cancer [8,24].

A decrease in islet mass and/or β-cell dysfunction is a pathogenetic mechanism for type 2 diabetes mellitus [25]. In the present study we found a significant fall in β-cell function for the occurrence of HCC. In the present study IR was found in 80% of cases of HCC, and most of the cases had low MELD and CTP score. It is therefore suggested that IR, primarily seen in type 2 diabetes mellitus, might have a role in hepatic carcinogenesis. IR with compensatory hyperinsulinemia has been implicated in the etiology of certain cancers, including colon, endometrial, possibly pancreatic, renal-cell cancers and breast cancer [8,24].

Summary Box

What is already known:

- Insulin resistance is common in cirrhosis due to hepatitis C (HCV), non-alcoholic fatty liver disease (NAFLD), autoimmune hepatitis (AIH) but unclear in hepatitis B (HBV) and alcoholic liver disease (ALD)
- Hyperinsulinemia in cirrhosis is a consequence of increased pancreatic insulin secretion or decreased hepatic insulin removal is unclear

What the new findings are:

- Insulin resistance in varied euglycemic cirrhosis is HCV (100%), NAFLD (100%), AIH (100%), hepatocellular carcinoma (80%), ALD (72%) and HBV (45%)
- Insulin resistance and pancreatic β-cell function is raised in Child Turcotte Pugh score >9 and model for end-stage liver disease score >15
- β-Cell function loss is associated with development of hepatogenous diabetes
(HOMA-β) in diabetic controls as compared to the euglycemic cirrhotic patients (P<0.0001) and no rise in β-cell function was seen with rise in CTP or MELD score. The study conducted by Greco et al suggested that hyperinsulinemia, at least in CTP grade B cirrhotic patients is the consequence of increased β-cell sensitivity to glucose, while hepatic insulin extraction does not seem to play a significant part [26]. In the current study we found a significant increase in pancreatic β-cell function with increase in IR in cirrhotic patients with CTP ≥10 and MELD score >15.

In conclusion, our study justifies the hypothesis that with advancement of liver disease there is progressive increase in IR and also compensatory increase in pancreatic β-cell function occurs which counteracts IR at the receptor level. However, with prolonged or sustained IR pancreatic β-cell function loss occurs, which may result in the development of hepaticogous diabetes.

Acknowledgement

The support of postgraduate students of Department of Medicine, Dr Sampurnanand Medical College, is keenly appreciated.

References

1. Bohan EM. Diabetes mellitus and cirrhosis of the liver: a case report. Del Med J 1947;19:212-215.
2. Megyesi C, Samols E, Marks V. Glucose tolerance and diabetes in chronic liver disease. Lancet 1967;2:1051-1056.
3. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460-468.
4. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007;30:734-743.
5. El-Serag HB, Everhart JE. Diabetes increases the risk of acute hepatic failure. Gastroenterology 2002;122:1822-1828.
6. Holstein A, Hinze S, Thiessen E, Plaschke A, Egberts EH. Clinical implications of hepatoegenic diabetes in liver cirrhosis. J Gastroenterol Hepatol 2002;17:677-681.
7. Cefalu WT. Insulin resistance: cellular and clinical concepts. Exp Biol Med (Maywood) 2001;226:13-26.
8. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 2004;33:283-303.
9. Zick Y. Ser/Thr phosphorylation of IRS proteins: a molecular basis for insulin resistance. Sci STKE 2005;2005:pe4.
10. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26:55-520.
11. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
12. Chitiuri S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35:373-379.
13. Chen H, Sullivan G, Quon MJ. Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration model. Diabetes 2005;54:1914-1925.
14. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-1495.
15. Duseja A, Thumberu KK, Das A, et al. Insulin tolerance test is comparable to homeostasis model assessment for insulin resistance in patients with non alcoholic fatty liver disease. Indian J Gastroenterol 2001;26:171-174.
16. Petta S, Cammà C, Di Marco V, et al. Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. Liver Int 2011;31:567-575.
17. Cua IH, Hui JM, Kench JG, George J. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology 2008;48:723-731.
18. de la Monte SM, Yeon JE, Tong M, et al. Insulin resistance in experimental alcohol-induced liver disease. J Gastroenterol Hepatol 2008;23:e477-e486.
19. Ronis MJ, Wands JR, Badger TM, de la Monte SM, Lang CH, Calissendorff J. Alcohol-induced disruption of endocrine signaling. Alcohol Clin Exp Res 2007;31:1269-1285.
20. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011;141:1572-1585.
21. Duseja A, Das A, Dhiman RK, et al. Indian patients with nonalcoholic fatty liver disease presenting with raised transaminases are different at presentation. World J Gastroenterol 2007;13:649-650.
22. Day C, James O. Steatohepatitis: a tale of two “hits”? Gastroenterology 1998;114:842-845.
23. Donadon V, Balbi M, Casarin P, Vario A, Alberti A. Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: Potential role of insulin. World J Gastroenterol 2008;14:5695-5700.
24. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-591.
25. Abdel-Halim SM, Guenifi A, Khan A, et al. Impaired coupling of glucose signal to the exocytotic machinery in diabetic GK rats: a defect ameliorated by cAMP. Diabetes 1996;45:934-940.
26. Greco AV, Mingrone G, Mari A, Capristo E, Manco M, Gabarrini G. Mechanisms of hyperinsulinemia in child’s disease grade B liver cirrhosis investigated in free living conditions. Gut 2002;51:870-875.